The human BDNF gene: peripheral gene expression and protein levels as biomarkers for psychiatric disorders

Translational Psychiatry

Volumn 6, Issue 11, 2016, Pages

  Cattaneo, A ^a,b   Cattane, N ^a   Begni, V ^c   Pariante, C M ^b   Riva, M A ^c  

^a IRCCS ISTITUTO CENTRO SAN GIOVANNI DI DIO FATEBENEFRATELLI   (Italy)

^b KING'S COLLEGE LONDON   (United Kingdom)

^c UNIVERSITY OF MILAN   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANIMAL; BRAIN; GENE EXPRESSION REGULATION; GENETIC EPIGENESIS; GENETIC MARKER; GENETIC TRANSCRIPTION; GENETICS; HUMAN; MENTAL DISEASE; METABOLISM; REFERENCE VALUE;

ANIMALS; BRAIN; EPIGENESIS, GENETIC; GENE EXPRESSION REGULATION; GENETIC MARKERS; HUMANS; MENTAL DISORDERS; REFERENCE VALUES; TRANSCRIPTION, GENETIC;

EID: 85014517698     PISSN: None     EISSN: 21583188     Source Type: Journal    
DOI: 10.1038/TP.2016.214     Document Type: Review

References (115)

1. Yoshii A, Constantine-Paton M. Postsynaptic BDNF-TrkB signaling in synapse maturation, plasticity, and disease. Dev Neurobiol 2010; 70: 304–322.
2. Hempstead BL. Brain-derived neurotrophic factor: three ligands, many actions. Trans Am Clin Clim Assoc 2015; 126: 9–19.
3. Polyakova M, Stuke K, Schuemberg K, Mueller K, Schoenknecht P, Schroeter ML. BDNF as a biomarker for successful treatment of mood disorders: a systematic & quantitative meta-analysis. J Affect Disord 2015; 174: 432–440.
4. Mitchelmore C, Gede L. Brain derived neurotrophic factor: epigenetic regulation in psychiatric disorders. Brain Res 2014; 1586: 162–172.
5. Autry AE, Monteggia LM. Brain-derived neurotrophic factor and neuropsychiatric disorders. Pharmacol Rev 2012; 64: 238–258.
6. Briand LA, Blendy JA. Molecular and genetic substrates linking stress and addiction. Brain Res 2010; 1314: 219–234.
7. Monteleone P, Maj M. Dysfunctions of leptin, ghrelin, BDNF and endocannabi-noids in eating disorders: beyond the homeostatic control of food intake. Psy-choneuroendocrinology 2013; 38: 312–330.
8. Dwivedi Y, Rizavi HS, Conley RR, Roberts RC, Tamminga CA, Pandey GN. Altered gene expression of brain-derived neurotrophic factor and receptor tyrosine kinase B in postmortem brain of suicide subjects. Arch Gen Psychiatry 2003; 60: 804–815.
9. Castren E. Neurotrophins as mediators of drug effects on mood, addiction, and neuroprotection. Mol Neurobiol 2004; 29: 289–302.
10. Pandey GN, Ren X, Rizavi HS, Conley RR, Roberts RC, Dwivedi Y. Brain-derived neurotrophic factor and tyrosine kinase B receptor signalling in post-mortem brain of teenage suicide victims. Int J Neuropsychopharmacol 2008; 11: 1047–1061.
11. Sen S, Duman R, Sanacora G. Serum brain-derived neurotrophic factor, depres-sion, and antidepressant medications: meta-analyses and implications. Biol Psychiatry 2008; 64: 527–532.
12. Bocchio-Chiavetto L, Bagnardi V, Zanardini R, Molteni R, Nielsen MG, Placentino A et al. Serum and plasma BDNF levels in major depression: a replication study and meta-analyses. World J Biol Psychiatry 2010; 11: 763–773.
13. Cattaneo A, Bocchio-Chiavetto L, Zanardini R, Milanesi E, Placentino A, Gennarelli M. Reduced peripheral brain-derived neurotrophic factor mRNA levels are nor-malized by antidepressant treatment. Int J Neuropsychopharmacol 2010; 13: 103–108.
14. Cattaneo A, Gennarelli M, Uher R, Breen G, Farmer A, Aitchison KJ et al. Candidate genes expression profile associated with antidepressants response in the GENDEP study: differentiating between baseline 'predictors' and longitudinal 'targets'. Neuropsychopharmacology 2013; 38: 377–385.
15. Luoni A, Macchi F, Papp M, Molteni R, Riva MA. Lurasidone exerts antidepressant properties in the chronic mild stress model through the regulation of synaptic and neuroplastic mechanisms in the rat prefrontal cortex. Int J Neuropsycho-pharmacol 2015; 18: pii: pyu061.
16. Calabrese F, van der Doelen RH, Guidotti G, Racagni G, Kozicz T, Homberg JR et al. Exposure to early life stress regulates Bdnf expression in SERT mutant rats in an anatomically selective fashion. J Neurochem 2015; 132: 146–154.
17. Roceri M, Cirulli F, Pessina C, Peretto P, Racagni G, Riva MA. Postnatal repeated maternal deprivation produces age-dependent changes of brain-derived neu-rotrophic factor expression in selected rat brain regions. Biol Psychiatry 2004; 55: 708–714.
18. Calabrese F, Molteni R, Cattaneo A, Macchi F, Racagni G, Gennarelli M et al. Long-Term duloxetine treatment normalizes altered brain-derived neurotrophic factor expression in serotonin transporter knockout rats through the modulation of specific neurotrophin isoforms. Mol Pharmacol 2010; 77: 846–853.
19. Schmidt HD, Duman RS. The role of neurotrophic factors in adult hippocampal neurogenesis, antidepressant treatments and animal models of depressive-like behavior. Behav Pharmacol 2007; 18: 391–418.
20. Polyakova M, Schroeter ML, Elzinga BM, Holiga S, Schoenknecht P, de Kloet ER et al. Brain-derived neurotrophic factor and antidepressive effect of electro-convulsive therapy: systematic review and meta-analyses of the preclinical and clinical literature. PLoS One 2015; 10: e0141564.
21. Bus BA, Molendijk ML, Tendolkar I, Penninx BW, Prickaerts J, Elzinga BM et al. Chronic depression is associated with a pronounced decrease in serum brain-derived neurotrophic factor over time. Mol Psychiatry 2015; 20: 602–608.
22. Molendijk ML, Bus BA, Spinhoven P, Penninx BW, Kenis G, Prickaerts J et al. Serum levels of brain-derived neurotrophic factor in major depressive disorder: state-trait issues, clinical features and pharmacological treatment. Mol Psychiatry 2011; 16: 1088–1095.
23. Takahashi M, Shirakawa O, Toyooka K, Kitamura N, Hashimoto T, Maeda K et al. Abnormal expression of brain-derived neurotrophic factor and its receptor in the corticolimbic system of schizophrenic patients. Mol Psychiatry 2000; 5: 293–300.
24. Iritani S, Niizato K, Nawa H, Ikeda K, Emson PC. Immunohistochemical study of brain-derived neurotrophic factor and its receptor, TrkB, in the hippocampal formation of schizophrenic brains. Progr Neuropsychopharmacol Biol Psychiatry 2003; 27: 801–807.
25. Durany N, Michel T, Zochling R, Boissl KW, Cruz-Sanchez FF, Riederer P et al. Brain-derived neurotrophic factor and neurotrophin 3 in schizophrenic psy-choses. Schizoph Res 2001; 52: 79–86.
26. Weickert CS, Hyde TM, Lipska BK, Herman MM, Weinberger DR, Kleinman JE. Reduced brain-derived neurotrophic factor in prefrontal cortex of patients with schizophrenia. Mol Psychiatry 2003; 8: 592–610.
27. Hashimoto T, Bergen SE, Nguyen QL, Xu B, Monteggia LM, Pierri JN et al. Relationship of brain-derived neurotrophic factor and its receptor TrkB to altered inhibitory prefrontal circuitry in schizophrenia. J Neurosci 2005; 25: 372–383.
28. Pillai A, Dhandapani KM, Pillai BA, Terry AV Jr., Mahadik SP. Erythropoietin pre-vents haloperidol treatment-induced neuronal apoptosis through regulation of BDNF. Neuropsychopharmacology 2008; 33: 1942–1951.
29. Durany N, Thome J. Neurotrophic factors and the pathophysiology of schizophrenic psychoses. Eur Psychiatry 2004; 19: 326–337.
30. Green MJ, Matheson SL, Shepherd A, Weickert CS, Carr VJ. Brain-derived neu-rotrophic factor levels in schizophrenia: a systematic review with meta-analysis. Mol Psychiatry 2011; 16: 960–972.
31. Fernandes BS, Steiner J, Berk M, Molendijk ML, Gonzalez-Pinto A, Turck CW et al. Peripheral brain-derived neurotrophic factor in schizophrenia and the role of anti-psychotics: meta-analysis and implications. Mol Psychiatry 2015; 20: 1108–1119.
32. Fernandes BS, Molendijk ML, Kohler CA, Soares JC, Leite CM, Machado-Vieira R et al. Peripheral brain-derived neurotrophic factor (BDNF) as a biomarker in bipolar disorder: a meta-analysis of 52 studies. BMC Med 2015; 13: 289.
33. Kauer-Sant'Anna M, Kapczinski F, Andreazza AC, Bond DJ, Lam RW, Young LT et al. Brain-derived neurotrophic factor and inflammatory markers in patients with early-vs. late-stage bipolar disorder. Int J Neuropsychopharmacol 2009; 12: 447–458.
34. Kose Cinar R, Sonmez MB, Gorgulu Y. Peripheral blood mRNA expressions of stress biomarkers in manic episode and subsequent remission. Psychoneur-oendocrinology 2016; 70: 10–16.
35. Molendijk ML, Bus BA, Spinhoven P, Penninx BW, Prickaerts J, Oude Voshaar RC et al. Gender specific associations of serum levels of brain-derived neurotrophic factor in anxiety. World J Biol Psychiatry 2012; 13: 535–543.
36. Carlino D, Francavilla R, Baj G, Kulak K, d'Adamo P, Ulivi S et al. Brain-derived neurotrophic factor serum levels in genetically isolated populations: gender-specific association with anxiety disorder subtypes but not with anxiety levels or Val66Met polymorphism. PeerJ 2015; 3: e1252.
37. Uguz F, Sonmez EO, Sahingoz M, Gokmen Z, Basaran M, Gezginc K et al. Maternal generalized anxiety disorder during pregnancy and fetal brain development: a comparative study on cord blood brain-derived neurotrophic factor levels. J Psychosom Res 2013; 75: 346–350.
38. Hemmings SM, Kinnear CJ, Van der Merwe L, Lochner C, Corfield VA, Moolman-Smook JC et al. Investigating the role of the brain-derived neurotrophic factor (BDNF) val66met variant in obsessive-compulsive disorder (OCD). World J Biol Psychiatry 2008; 9: 126–134.
39. Simsek S, Gencoglan S, Yuksel T, Kaplan I, Alaca R. Cortisol and brain-derived neurotrophic factor levels prior to treatment in children with obsessive-compulsive disorder. J Clin Psychiatry 2016; 77: e855–e859.
40. Pruunsild P, Kazantseva A, Aid T, Palm K, Timmusk T. Dissecting the human BDNF locus: bidirectional transcription, complex splicing, and multiple promoters. Genomics 2007; 90: 397–406.
41. Adachi N, Numakawa T, Richards M, Nakajima S, Kunugi H. New insight in expression, transport, and secretion of brain-derived neurotrophic factor: Implications in brain-related diseases. World J Biol Chem 2014; 5: 409–428.
42. Lessmann V, Brigadski T. Mechanisms, locations, and kinetics of synaptic BDNF secretion: an update. Neurosci Res 2009; 65: 11–22.
43. Mowla SJ, Farhadi HF, Pareek S, Atwal JK, Morris SJ, Seidah NG et al. Biosynthesis and post-translational processing of the precursor to brain-derived neurotrophic factor. J Biol Chem 2001; 276: 12660–12666.
44. Lee R, Kermani P, Teng KK, Hempstead BL. Regulation of cell survival by secreted proneurotrophins. Science 2001; 294: 1945–1948.
45. Yang J, Harte-Hargrove LC, Siao CJ, Marinic T, Clarke R, Ma Q et al. proBDNF negatively regulates neuronal remodeling, synaptic transmission, and synaptic plasticity in hippocampus. Cell Rep 2014; 7: 796–806.
46. Hong EJ, McCord AE, Greenberg ME. A biological function for the neuronal activity-dependent component of Bdnf transcription in the development of cortical inhibition. Neuron 2008; 60: 610–624.
47. Gass P, Hellweg R. Peripheral brain-derived neurotrophic factor (BDNF) as a biomarker for affective disorders? Int J Neuropsychopharmacol 2010; 13: 1–4.
48. Nikolova YS, Hariri AR. Can we observe epigenetic effects on human brain function? Trends Cogn Sci 2015; 19: 366–373.
49. Lardenoije R, Iatrou A, Kenis G, Kompotis K, Steinbusch HW, Mastroeni D et al. The epigenetics of aging and neurodegeneration. Progr Neurobiol 2015; 131: 21–64.
50. Tsankova N, Renthal W, Kumar A, Nestler EJ. Epigenetic regulation in psychiatric disorders. Nat Rev Neurosci 2007; 8: 355–367.
51. Keller S, Sarchiapone M, Zarrilli F, Videtic A, Ferraro A, Carli V et al. Increased BDNF promoter methylation in the Wernicke area of suicide subjects. Arch Gen Psychiatry 2010; 67: 258–267.
52. Keleshian VL, Modi HR, Rapoport SI, Rao JS. Aging is associated with altered inflammatory, arachidonic acid cascade, and synaptic markers, influenced by epigenetic modifications, in the human frontal cortex. J Neurochem 2013; 125: 63–73.
53. Mill J, Tang T, Kaminsky Z, Khare T, Yazdanpanah S, Bouchard L et al. Epigenomic profiling reveals DNA-methylation changes associated with major psychosis. Am J Hum Genet 2008; 82: 696–711.
54. Mellios N, Huang HS, Grigorenko A, Rogaev E, Akbarian S. A set of differentially expressed miRNAs, including miR-30a-5p, act as post-transcriptional inhibitors of BDNF in prefrontal cortex. Hum Mol Genet 2008; 17: 3030–3042.
55. Chen ES, Ernst C, Turecki G. The epigenetic effects of antidepressant treatment on human prefrontal cortex BDNF expression. Int J Neuropsychopharmacol 2011; 14: 427–429.
56. Lopez JP, Mamdani F, Labonte B, Beaulieu MM, Yang JP, Berlim MT et al. Epigenetic regulation of BDNF expression according to antidepressant response. Mol Psychiatry 2013; 18: 398–399.
57. Lang MF, Shi Y. Dynamic Roles of microRNAs in Neurogenesis. Front Neurosci 2012; 6: 71.
58. Sun E, Shi Y. MicroRNAs: small molecules with big roles in neurodevelopment and diseases. Exp Neurol 2015; 268: 46–53.
59. Kosik KS. The neuronal microRNA system. Nat Rev Neurosci 2006; 7: 911–920.
60. Shi Y, Zhao X, Hsieh J, Wichterle H, Impey S, Banerjee S et al. MicroRNA regulation of neural stem cells and neurogenesis. J Neurosci 2010; 30: 14931–14936.
61. Mellios N, Huang HS, Baker SP, Galdzicka M, Ginns E, Akbarian S. Molecular determinants of dysregulated GABAergic gene expression in the prefrontal cortex of subjects with schizophrenia. Biol Psychiatry 2009; 65: 1006–1014.
62. Dwivedi Y. Pathogenetic and therapeutic applications of microRNAs in major depressive disorder. Progr Neuropsychopharmacol Biol Psychiatry 2016; 64: 341–348.
63. Liang Y, Zhao G, Sun R, Mao Y, Li G, Chen X et al. Genetic variants in the promoters of let-7 family are associated with an increased risk of major depressive disorder. J Affect Disord 2015; 183: 295–299.
64. Walker RM, Rybka J, Anderson SM, Torrance HS, Boxall R, Sussmann JE et al. Preliminary investigation of miRNA expression in individuals at high familial risk of bipolar disorder. J Psychiatr Res 2015; 62: 48–55.
65. Hunsberger JG, Chibane FL, Elkahloun AG, Henderson R, Singh R, Lawson J et al. Novel integrative genomic tool for interrogating lithium response in bipolar disorder. Transl Psychiatry 2015; 5: e504.
66. Mellios N, Sur M. The emerging role of microRNAs in schizophrenia and autism spectrum disorders. Front Psychiatry 2012; 3: 39.
67. Varendi K, Matlik K, Andressoo JO. From microRNA target validation to therapy: lessons learned from studies on BDNF. Cell Mol Life Sci 2015; 72: 1779–1794.
68. Brandenburger T, Grievink H, Heinen N, Barthel F, Huhn R, Stachuletz F et al. Effects of remote ischemic preconditioning and myocardial ischemia on microRNA-1 expression in the rat heart in vivo. Shock 2014; 42: 234–238.
69. Radzikinas K, Aven L, Jiang Z, Tran T, Paez-Cortez J, Boppidi K et al. A Shh/ miR-206/BDNF cascade coordinates innervation and formation of airway smooth muscle. J Neurosci 2011; 31: 15407–15415.
70. Lee ST, Chu K, Jung KH, Kim JH, Huh JY, Yoon H et al. miR-206 regulates brain-derived neurotrophic factor in Alzheimer disease model. Ann Neurol 2012; 72: 269–277.
71. Tapocik JD, Barbier E, Flanigan M, Solomon M, Pincus A, Pilling A et al. MicroRNA-206 in rat medial prefrontal cortex regulates BDNF expression and alcohol drinking. J Neurosci 2014; 34: 4581–4588.
72. Kim HK, Lee YS, Sivaprasad U, Malhotra A, Dutta A. Muscle-specific microRNA miR-206 promotes muscle differentiation. J Cell Biol 2006; 174: 677–687.
73. Miura P, Amirouche A, Clow C, Belanger G, Jasmin BJ. Brain-derived neurotrophic factor expression is repressed during myogenic differentiation by miR-206. J Neurochem 2012; 120: 230–238.
74. Imam JS, Plyler JR, Bansal H, Prajapati S, Bansal S, Rebeles J et al. Genomic loss of tumor suppressor miRNA-204 promotes cancer cell migration and invasion by activating AKT/mTOR/Rac1 signaling and actin reorganization. PLoS One 2012; 7: e52397.
75. Fasanaro P, Greco S, Lorenzi M, Pescatori M, Brioschi M, Kulshreshtha R et al. An integrated approach for experimental target identification of hypoxia-induced miR-210. J Biol Chem 2009; 284: 35134–35143.
76. Darcq E, Warnault V, Phamluong K, Besserer GM, Liu F, Ron D. MicroRNA-30a-5p in the prefrontal cortex controls the transition from moderate to excessive alcohol consumption. Mol Psychiatry 2015; 20: 1219–1231.
77. Lau AG, Irier HA, Gu J, Tian D, Ku L, Liu G et al. Distinct 3'UTRs differentially regulate activity-dependent translation of brain-derived neurotrophic factor (BDNF). Proc Natl Acad Sci USA 2010; 107: 15945–15950.
78. Calabrese F, Richetto J, Racagni G, Feldon J, Meyer U, Riva MA. Effects of with-drawal from repeated amphetamine exposure in peri-puberty on neuroplasticity-related genes in mice. Neuroscience 2013; 250: 222–231.
79. Li YJ, Xu M, Gao ZH, Wang YQ, Yue Z, Zhang YX et al. Alterations of serum levels of BDNF-related miRNAs in patients with depression. PLoS One 2013; 8: e63648.
80. Launay JM, Mouillet-Richard S, Baudry A, Pietri M, Kellermann O. Raphe-mediated signals control the hippocampal response to SRI antidepressants via miR-16. Transl Psychiatry 2011; 1: e56.
81. Bai M, Zhu X, Zhang Y, Zhang S, Zhang L, Xue L et al. Abnormal hippocampal BDNF and miR-16 expression is associated with depression-like behaviors induced by stress during early life. PLoS One 2012; 7: e46921.
82. Hsu SD, Huang HY, Chou CH, Sun YM, Hsu MT, Tsou AP. Integrated analyses to reconstruct microRNA-mediated regulatory networks in mouse liver using high-throughput profiling. BMC Genomics 2015; 16(Suppl 2): S12.
83. Davis J, Maes M, Andreazza A, McGrath JJ, Tye SJ, Berk M. Towards a classification of biomarkers of neuropsychiatric disease: from encompass to compass. Mol Psychiatry 2015; 20: 152–153.
84. Pillai A, Buckley PF. Reliable biomarkers and predictors of schizophrenia and its treatment. Psychiatr Clin N Am 2012; 35: 645–659.
85. Schmidt HD, Shelton RC, Duman RS. Functional biomarkers of depression: diagnosis, treatment, and pathophysiology. Neuropsychopharmacology 2011; 36: 2375–2394.
86. Frodl T, Skokauskas N, Frey EM, Morris D, Gill M, Carballedo A. BDNF Val66Met genotype interacts with childhood adversity and influences the formation of hippocampal subfields. Hum Brain Mapp 2014; 35: 5776–5783.
87. Carballedo A, Morris D, Zill P, Fahey C, Reinhold E, Meisenzahl E et al. Brain-derived neurotrophic factor Val66Met polymorphism and early life adversity affect hippocampal volume. Am J Mel Genet B 2013; 162B: 183–190.
88. Pregelj P, Nedic G, Paska AV, Zupanc T, Nikolac M, Balazic J et al. The association between brain-derived neurotrophic factor polymorphism (BDNF Val66Met) and suicide. J Affect Disord 2011; 128: 287–290.
89. Grabe HJ, Schwahn C, Mahler J, Appel K, Schulz A, Spitzer C et al. Genetic epistasis between the brain-derived neurotrophic factor Val66Met polymorph-ism and the 5-HTT promoter polymorphism moderates the susceptibility to depressive disorders after childhood abuse. Progr Neuropsychopharmacol Biol Psychiatry 2012; 36: 264–270.
90. Aguilera M, Arias B, Wichers M, Barrantes-Vidal N, Moya J, Villa H et al. Early adversity and 5-HTT/BDNF genes: new evidence of gene-environment interactions on depressive symptoms in a general population. Psychol Med 2009; 39: 1425–1432.
91. Savitz JB, van der Merwe L, Newman TK, Solms M, Stein DJ, Ramesar RS. The relationship between childhood abuse and dissociation. Is it influenced by catechol-O-methyltransferase (COMT) activity? Int J Neuropsychopharmacol 2008; 11: 149–161.
92. Altar CA. Neurotrophins and depression. Trends Pharmacol Sci 1999; 20: 59–61.
93. Duman RS, Heninger GR, Nestler EJ. A molecular and cellular theory of depres-sion. Arch Gen Psychiatry 1997; 54: 597–606.
94. Burbach GJ, Hellweg R, Haas CA, Del Turco D, Deicke U, Abramowski D et al. Induction of brain-derived neurotrophic factor in plaque-associated glial cells of aged APP23 transgenic mice. J Neurosci 2004; 24: 2421–2430.
95. Kumarasinghe N, Tooney PA, Schall U. Finding the needle in the haystack: a review of microarray gene expression research into schizophrenia. Aust N Z J Psychiatry 2012; 46: 598–610.
96. Mistry M, Gillis J, Pavlidis P. Genome-wide expression profiling of schizophrenia using a large combined cohort. Mol Psychiatry 2013; 18: 215–225.
97. Brunoni AR, Lopes M, Fregni F. A systematic review and meta-analysis of clinical studies on major depression and BDNF levels: implications for the role of neuro-plasticity in depression. Int J Neuropsychopharmacol 2008; 11: 1169–1180.
98. Karege F, Perret G, Bondolfi G, Schwald M, Bertschy G, Aubry JM. Decreased serum brain-derived neurotrophic factor levels in major depressed patients. Psychiatry Res 2002; 109: 143–148.
99. Karege F, Bondolfi G, Gervasoni N, Schwald M, Aubry JM, Bertschy G. Low brain-derived neurotrophic factor (BDNF) levels in serum of depressed patients probably results from lowered platelet BDNF release unrelated to platelet reactivity. Biol Psychiatry 2005; 57: 1068–1072.
100. Pandey GN, Dwivedi Y, Rizavi HS, Ren X, Zhang H, Pavuluri MN. Brain-derived neurotrophic factor gene and protein expression in pediatric and adult depressed subjects. Progr Neuropsychopharmacol Biol Psychiatry 2010; 34: 645–651.
101. Molendijk ML, Spinhoven P, Polak M, Bus BA, Penninx BW, Elzinga BM. Serum BDNF concentrations as peripheral manifestations of depression: evidence from a systematic review and meta-analyses on 179 associations (N = 9484). Mol Psychiatry 2014; 19: 791–800.
102. Ahmed AO, Mantini AM, Fridberg DJ, Buckley PF. Brain-derived neurotrophic factor (BDNF) and neurocognitive deficits in people with schizophrenia: a meta-analysis. Psychiatry Res 2015; 226: 1–13.
103. Toll A, Mane A. Brain-derived neurotrophic factor levels in first episode of psy-chosis: a systematic review. World J Psychiatry 2015; 5: 154–159.
104. Pan W, Banks WA, Fasold MB, Bluth J, Kastin AJ. Transport of brain-derived neurotrophic factor across the blood-brain barrier. Neuropharmacology 1998; 37: 1553–1561.
105. Lang UE, Hellweg R, Seifert F, Schubert F, Gallinat J. Correlation between serum brain-derived neurotrophic factor level and an in vivo marker of cortical integ-rity. Biological psychiatry 2007; 62: 530–535.
106. Fujimura H, Altar CA, Chen R, Nakamura T, Nakahashi T, Kambayashi J et al. Brain-derived neurotrophic factor is stored in human platelets and released by agonist stimulation. Thromb Haemostasis 2002; 87: 728–734.
107. Pliego-Rivero FB, Bayatti N, Giannakoulopoulos X, Glover V, Bradford HF, Stern G et al. Brain-derived neurotrophic factor in human platelets. Biochem Pharmacol 1997; 54: 207–209.
108. Lee BH, Kim YK. Reduced platelet BDNF level in patients with major depression. Progr Neuropsychopharmacol Biol Psychiatry 2009; 33: 849–853.
109. Rollins B, Martin MV, Morgan L, Vawter MP. Analysis of whole genome biomarker expression in blood and brain. Am J Med Genet B 2010; 153B: 919–936.
110. Sullivan PF, Fan C, Perou CM. Evaluating the comparability of gene expression in blood and brain. Am J Med Genet B 2006; 141B: 261–268.
111. Tylee DS, Kawaguchi DM, Glatt SJ. On the outside, looking in: a review and evaluation of the comparability of blood and brain ‘-omes’. Am J Med Genet B 2013; 162B: 595–603.
112. Gardiner EJ, Cairns MJ, Liu B, Beveridge NJ, Carr V, Kelly B et al. Gene expression analysis reveals schizophrenia-associated dysregulation of immune pathways in peripheral blood mononuclear cells. J Psychiatr Res 2013; 47: 425–437.
113. Glatt SJ, Stone WS, Nossova N, Liew CC, Seidman LJ, Tsuang MT. Similarities and differences in peripheral blood gene-expression signatures of individuals with schizophrenia and their first-degree biological relatives. Am J Med Genet B 2011; 156B: 869–887.
114. Bus BA, Molendijk ML, Penninx BJ, Buitelaar JK, Kenis G, Prickaerts J et al. Determinants of serum brain-derived neurotrophic factor. Psychoneur-oendocrinology 2011; 36: 228–239.
115. Molendijk ML, Haffmans JP, Bus BA, Spinhoven P, Penninx BW, Prickaerts J et al. Serum BDNF concentrations show strong seasonal variation and correlations with the amount of ambient sunlight. PLoS One 2012; 7: e48046.